Quarterly report · Q1

Period2023-04-01 → 2023-06-30
Filed2023-08-07
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 31
MetricValuePeriodScopeSource row
Revenue¥16.0bn2023-04-01 → 2023-06-30Cons.Net sales
Revenue¥60.5bn2022-04-01 → 2023-03-31Cons.Net sales (5-year summary)
Revenue¥15.3bn2022-04-01 → 2022-06-30Cons.Net sales
Operating income¥1.7bn2023-04-01 → 2023-06-30Cons.Operating income
Operating income¥1.7bn2022-04-01 → 2022-06-30Cons.Operating income
Ordinary income¥1.8bn2023-04-01 → 2023-06-30Cons.Ordinary income
Ordinary income¥5.2bn2022-04-01 → 2023-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥1.8bn2022-04-01 → 2022-06-30Cons.Ordinary income
Profit before tax¥1.9bn2023-04-01 → 2023-06-30Cons.Income before income taxes
Profit before tax¥1.8bn2022-04-01 → 2022-06-30Cons.Income before income taxes
Net income (owners)¥1.4bn2023-04-01 → 2023-06-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥4.2bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥1.3bn2022-04-01 → 2022-06-30Cons.Profit loss attributable to owners of parent
Net income¥1.4bn2023-04-01 → 2023-06-30Cons.Profit loss
Net income¥1.3bn2022-04-01 → 2022-06-30Cons.Profit loss
Total assets¥89.2bnat 2023-06-30Cons.Assets
Total assets¥87.1bnat 2023-03-31Cons.Assets
Total assets¥84.8bnat 2022-06-30Cons.Total assets (5-year summary)
Total liabilities¥32.3bnat 2023-06-30Cons.Liabilities
Total liabilities¥32.6bnat 2023-03-31Cons.Liabilities
Net assets / equity¥56.9bnat 2023-06-30Cons.Net assets
Net assets / equity¥54.5bnat 2023-03-31Cons.Net assets
Net assets / equity¥50.5bnat 2022-06-30Cons.Net assets (5-year summary)
Cash and deposits¥15.2bnat 2023-06-30Cons.Cash and deposits
Cash and deposits¥14.5bnat 2023-03-31Cons.Cash and deposits
EPS (basic)¥50.512023-04-01 → 2023-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥150.082022-04-01 → 2023-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥46.942022-04-01 → 2022-06-30Cons.Basic earnings loss per share (5-year summary)
Equity ratio63.8%at 2023-06-30Cons.Equity to asset ratio (5-year summary)
Equity ratio62.6%at 2023-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio59.6%at 2022-06-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 34
SegmentItemPeriodValue
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2023-04-01 → 2023-06-30¥55m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2023-04-01 → 2023-06-30¥42m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2023-04-01 → 2023-06-30¥13m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2023-04-01 → 2023-06-30−¥27m
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-06-30−¥13m
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-06-30−¥13m
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-06-30−¥288m
jpcrp040300-q1r_E35791-000Animal Health Businessreportable segmentrevenue2023-04-01 → 2023-06-30¥1.6bn
jpcrp040300-q1r_E35791-000Animal Health Businessreportable segmentrevenue external2023-04-01 → 2023-06-30¥1.6bn
jpcrp040300-q1r_E35791-000Animal Health Businessreportable segmentsegment profit2023-04-01 → 2023-06-30−¥1m
jpcrp040300-q1r_E35791-000Pharmaceutical Businessreportable segmentrevenue2023-04-01 → 2023-06-30¥14.4bn
jpcrp040300-q1r_E35791-000Pharmaceutical Businessreportable segmentrevenue external2023-04-01 → 2023-06-30¥14.4bn
jpcrp040300-q1r_E35791-000Pharmaceutical Businessreportable segmentsegment profit2023-04-01 → 2023-06-30¥2.0bn
Total Of Reportable Segments And Otherssegment totalrevenue2023-04-01 → 2023-06-30¥16.0bn
Total Of Reportable Segments And Otherssegment totalrevenue external2023-04-01 → 2023-06-30¥16.0bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2023-04-01 → 2023-06-30¥13m
Total Of Reportable Segments And Otherssegment totalsegment profit2023-04-01 → 2023-06-30¥2.0bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2022-04-01 → 2022-06-30¥44m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2022-04-01 → 2022-06-30¥29m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2022-04-01 → 2022-06-30¥15m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2022-04-01 → 2022-06-30−¥18m
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-06-30−¥15m
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-06-30−¥15m
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-06-30−¥169m
jpcrp040300-q1r_E35791-000Animal Health Businessreportable segmentrevenue2022-04-01 → 2022-06-30¥1.6bn
jpcrp040300-q1r_E35791-000Animal Health Businessreportable segmentrevenue external2022-04-01 → 2022-06-30¥1.6bn
jpcrp040300-q1r_E35791-000Animal Health Businessreportable segmentsegment profit2022-04-01 → 2022-06-30¥124m
jpcrp040300-q1r_E35791-000Pharmaceutical Businessreportable segmentrevenue2022-04-01 → 2022-06-30¥13.6bn
jpcrp040300-q1r_E35791-000Pharmaceutical Businessreportable segmentrevenue external2022-04-01 → 2022-06-30¥13.6bn
jpcrp040300-q1r_E35791-000Pharmaceutical Businessreportable segmentsegment profit2022-04-01 → 2022-06-30¥1.7bn
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-06-30¥15.3bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-06-30¥15.3bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-06-30¥15m
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-06-30¥1.8bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 323
ItemContextValueUnit
Number of shares held in own name treasury shares etcCurrentQuarterInstant2269100
Number of shares held in others names treasury shares etcCurrentQuarterInstant-
Total number of shares held treasury shares etcCurrentQuarterInstant2269100
Shareholding ratio treasury shares etcCurrentQuarterInstant0.0742
Cash and depositsPrior1YearInstant14505000000JPY
Cash and depositsCurrentQuarterInstant15183000000JPY
Accounts receivable tradePrior1YearInstant15217000000JPY
Accounts receivable tradeCurrentQuarterInstant16370000000JPY
Short term investment securitiesPrior1YearInstant3400000000JPY
Short term investment securitiesCurrentQuarterInstant2900000000JPY
Merchandise and finished goodsPrior1YearInstant10815000000JPY
Merchandise and finished goodsCurrentQuarterInstant10158000000JPY
Work in processPrior1YearInstant429000000JPY
Work in processCurrentQuarterInstant452000000JPY
Raw materials and suppliesPrior1YearInstant6443000000JPY
Raw materials and suppliesCurrentQuarterInstant6891000000JPY
Other caPrior1YearInstant2948000000JPY
Other caCurrentQuarterInstant3087000000JPY
Current assetsPrior1YearInstant53759000000JPY
Current assetsCurrentQuarterInstant55043000000JPY
Property plant and equipmentPrior1YearInstant10796000000JPY
Property plant and equipmentCurrentQuarterInstant10698000000JPY
Intangible assetsPrior1YearInstant4465000000JPY
Intangible assetsCurrentQuarterInstant4018000000JPY
Investment securitiesPrior1YearInstant14385000000JPY
Investment securitiesCurrentQuarterInstant16338000000JPY
Other ioaPrior1YearInstant3748000000JPY
Other ioaCurrentQuarterInstant3085000000JPY
Allowance for doubtful accounts ioa by groupPrior1YearInstant-17000000JPY
Allowance for doubtful accounts ioa by groupCurrentQuarterInstant-17000000JPY
Investments and other assetsPrior1YearInstant18117000000JPY
Investments and other assetsCurrentQuarterInstant19406000000JPY
Noncurrent assetsPrior1YearInstant33378000000JPY
Noncurrent assetsCurrentQuarterInstant34123000000JPY
AssetsPrior1YearInstant87138000000JPY
AssetsCurrentQuarterInstant89166000000JPY
Accounts payable tradePrior1YearInstant2838000000JPY
Accounts payable tradeCurrentQuarterInstant4843000000JPY
Electronically recorded obligations operating clPrior1YearInstant3022000000JPY
Electronically recorded obligations operating clCurrentQuarterInstant2677000000JPY
Short term loans payablePrior1YearInstant3438000000JPY
Short term loans payableCurrentQuarterInstant2885000000JPY
Other provision clPrior1YearInstant1167000000JPY
Other provision clCurrentQuarterInstant564000000JPY
Other clPrior1YearInstant7182000000JPY
Other clCurrentQuarterInstant7702000000JPY
Current liabilitiesPrior1YearInstant17650000000JPY
Current liabilitiesCurrentQuarterInstant18673000000JPY
Long term loans payablePrior1YearInstant9185000000JPY
Long term loans payableCurrentQuarterInstant7765000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2023-03-31pass rounding
balance sheet identityconsolidated 2023-06-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2023-03-31pass
statement vs summary · net assetsconsolidated 2023-06-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-06-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-06-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-06-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-06-30pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-06-30pass